评价帕妥珠单抗在HER2阳性胃癌患者中的安全性及有效性

1
查找项目通过临床招募信息库查项目

2
联系我们招募专员进行初筛

3
签署同意签署知情同意书

4
成功入组成功参加临床试验

试验详情
入选标准
排除标准
研究中心

试验详情

一、临床试验项目名称
评价帕妥珠单抗在HER2阳性胃癌患者中的安全性及有效性

二、适应症
HER2阳性的转移性胃食管交界处癌和胃癌

三、试验介绍

比较使用帕妥珠单抗+曲妥珠单抗（赫赛汀）+氟嘧啶+顺铂(TFP)治疗的患者与使用安慰剂+TFP治疗的患者的总生存期(OS)。

研究中心所在省份及城市（具体启动情况以后期咨询为准）

研究中心	主要研究者
北京肿瘤医院	沈琳

序号	机构名称	主要研究者	国家	省（州）	城市
1	北京肿瘤医院	沈琳	中国	北京	北京
2	中国医学科学院肿瘤医院	周爱萍	中国	北京	北京
3	复旦大学附属肿瘤医院	李进	中国	上海	上海
4	中国人民解放军三〇七医院	徐建明	中国	北京	北京
5	吉林省肿瘤医院	程颖	中国	吉林	长春
6	复旦大学附属中山医院	刘天舒	中国	上海	上海
7	中国人民解放军第八一医院	秦叔逵	中国	江苏	南京
8	中山大学附属肿瘤医院/中山大学肿瘤防治中心	徐瑞华	中国	广东	广州
9	南京军区福州总医院	欧阳学农	中国	福建	福州
10	吉林大学第一医院	李薇	中国	吉林	长春
11	中国人民解放军第三军医大学第三附属医院	王东	中国	重庆	重庆
12	浙江大学医学院附属邵逸夫医院	潘宏铭	中国	浙江	杭州
13	哈尔滨医科大学附属肿瘤医院	白玉贤	中国	黑龙江	哈尔滨
14	河南省肿瘤医院	杨树军	中国	河南	郑州
15	河北医科大学第四医院	刘巍	中国	河北	石家庄
16	福建省肿瘤医院	杨建伟	中国	福建	福州
17	中国人民解放军沈阳军区总医院	谢晓冬	中国	辽宁	沈阳
18	常州市第一人民医院	吴昌平	中国	江苏	常州
19	徐州医学院附属医院	高超	中国	江苏	徐州
20	郑州大学第一附属医院	秦艳茹	中国	河南	郑州
21	中国人民解放军第四军医大学第一附属医院（西京医院）	吴开春	中国	陕西	西安
22	南昌大学第一附属医院	熊建萍	中国	江西	南昌
23	南通市肿瘤医院	王建红	中国	江苏	南通
24	哈尔滨医科大学附属肿瘤医院	张艳桥	中国	黑龙江	哈尔滨
25	Austin Health; Cancer Clinical Trial Centre	NIALL TEBBUTT	AUSTRALIA	Victoria	Heidelberg
26	Royal Brisbane Womens Hosp; Division of Oncology	Matthew Burge	AUSTRALIA	Queensland	Herston
27	MONASH MEDICAL CENTRE; ONCOLOGY	Ben Markman	AUSTRALIA	Victoria	EAST BENTLEIGH
28	SIR CHARLES GAIRDNER HOSPITAL; MEDICAL ONCOLOGY	Kevin Jasas	AUSTRALIA	Western Australia	PERTH
29	KRANKENHAUS ST. VINZENZ DER BARMHERZIGEN SCHWESTERN ZAMS; ABT. FüR INNERE MEDIZIN	EWALD WOELL	AUSTRIA	ZAMS	ZAMS
30	LKH SALZBURG - UNIV. KLINIKUM SALZBURG; III. MEDIZINISCHE ABT.	RICHARD GREIL	AUSTRIA	Salzburg	Salzburg
31	CLINIQUES UNI IRES SAINT-LUC; ONCOLOGY	Marc Van den Eynde	BELGIUM	BRUXELLES	BRUXELLES
32	U.Z. GASTHUISBERG; GASTRO-ENTEROLOGIE	ERIC VAN CUTSEM	BELGIUM	LEUVEN	LEUVEN
33	Hospital A. C. Camargo; Oncologia	Celso Mello	BRAZIL	RS	Porto Alegre
34	Clinicas Oncologicas Integradas - COI	Fernando Vieira	BRAZIL	SP	Sao Paulo
35	Hospital das Clinicas - UFRGS	Rodrigo Pereira	BRAZIL	SP	Sao Paulo
36	Hospital Nossa Senhora da Conceicao	Carlos Gorini	BRAZIL	RJ	Rio De Janeiro
37	CLINICA DE ONCOLOGIA MEDICA	Artur Malzyner	BRAZIL	SP	Sao Paulo
38	Universidade Federal de Sao Paulo – UNIFESP	Nora Forones	BRAZIL	RS	Porto Alegre
39	Centro de Pesquisas Oncologicas - CEPON	Yeni Veronica Neron	BRAZIL	SC	Florianopolis
40	HOSPITAL SIRIO LIBANES; CENTRO DE ONCOLOGIA	Paulo Marcelo Hoff	BRAZIL	SP	Sao Paulo
41	Military Medical Academy- MHAT	Zhasmina Milanova	BULGARIA	Sofia	Sofia
42	SHATOD Dr. Marko Antonov Markov-Varna, EOOD; Department of Medicinall Onchotherapy and Palliative	VIOLINA TASKOVA	BULGARIA	Varna	Varna
43	MHAT Serdika	Krasimir Koynov	BULGARIA	Sofia	Sofia
44	DR. H. BLISS MURPHY CANCER CENTRE; ONCOLOGY	JEHAN SIDDIQUI	CANADA	Newfoundland	ST. JOHN'S
45	HAMILTON HEALTH SCIENCES - JURAVINSKI CANCER CENTRE	SUKHBINDER DHESY-THIND	CANADA	Ontario	HAMILTON
46	SUNNYBROOK HEALTH SCIENCE CENTRE	SCOTT BERRY	CANADA	Ontario	TORONTO
47	MOUNT SINAI HOSPITAL; ONCOLOGY	RONALD BURKES	CANADA	Ontario	TORONTO
48	McGill University; Montreal General Hosptial; Oncology	Thierry Alcindor	CANADA	Quebec	MONTREAL
49	Northeast Cancer Centre of Health Sciences North	Abderrahim Khomani	CANADA	Quebec	Sudbury
50	Clinical Hospital Sisters of Mercy	Jasna Radic	CROATIA	ZAGREB	ZAGREB
51	Clinical Hospital Centre Zagreb	Stjepko Plestina	CROATIA	Zagreb	Zagreb
52	Hospital Oncologia; Oncology	Finlander Rosales Osegueda	EL SALVADOR	El Salvador	El Salvador
53	TURKU UNI CENTRAL HOSPITAL; ONCOLOGY CLINICS	RAIJA RISTAM？KI	FINLAND	Turku	Turku
54	Docrates Cance Center	TUOMO ALANKO	FINLAND	Helsinki	Helsinki
55	Universit？tsklinikum Mannheim, Tagestherapiezentrum, Interdisziplin？res Tumorzentrum	Ralf Hofheinz	GERMANY	MAINZ	MAINZ
56	Universit？tsklinikum Hamburg-Eppendorf; Hubertus Wald Tumorzentrum	Alexander Stein	GERMANY	Mannheim	Mannheim
57	Klinik Esslingen; Klinik für Allgemeine Innere Medizin, Onkologie/Haematologie	Michael Geissler	GERMANY	Hamburg	Hamburg
58	Kliniken Ludwigsburg-Bietigheim gGmbH Klinikum Ludwigsburg	Nicole Prasnikar	GERMANY	Esslingen	Esslingen
59	Universitaetsklinikum Essen, Innere Klinik und Poliklinik fuer Tumorforschung	Stefan Kasper	GERMANY	Ludwigsburg	Ludwigsburg
60	Universit？tsklinikum Ulm; Zentrum für Innere Medizin Klinik für Innere Medizin I	Thomas Seufferlein	GERMANY	Essen	Essen
61	Charité-Universit？tsm. Berlin; Med. Klinik mit Schwerpunkt H？matologie, Onkologie und Tumorimmunolo.	Peter Thuss-Patience	GERMANY	Ulm	Ulm
62	Universitaetsklinikum Leipzig, Universitaeres Krebszentrum Leipzig (UCCL)	Florian Lordick	GERMANY	Berlin	Berlin
63	Kliniken Essen-Mitte, Evang. Huyssens-Stiftung, Klinik für Internistische Onkologie / Haematologie	Michael Stahl	GERMANY	Leipzig	Leipzig
64	UNIKLINIK MAINZ; II. MEDIZINISCHE KLINIK	Markus M？hler	GERMANY	Essen	Essen
65	Medical Solution; Hematology	Oscar Avendano Flores	GUATEMALA	Guatemala	Guatemala
66	Orszagos Onkologiai Intezet; B Belgyogyaszati, Onkologiai es Klinikai Farmakologiai Osztaly	ISTVAN LANG	HUNGARY	Budapest	Budapest
67	Semmelweis Egyetem, I. sz. Belgyógyászati Klinika, Onkológiai Részleg	MAGDOLNA DANK	HUNGARY	Budapest	Budapest
68	SZEGEDI TUDOMANYEGYETEM SZENT GYORGYI ALBERT ORVOS ES GYOGYSZERES; ONKOTERAPIAS KLINIKA	Laszlo Torday	HUNGARY	Szeged	Szeged
69	DEBRECENI EGYETEM ORVOS ES EGESZSEGTUDOMANYI CENTRUM; ONKOLOGIAI TANSZEK	Zsolt Horvath	HUNGARY	DEBRECEN	DEBRECEN
70	Borsod-Abauj-Zemplen Megyei Korhaz es Egyetemi Oktato Korhaz;Sugarterapias Klinikai Onkologiai Intez	Endre Oross	HUNGARY	MISKOLC	MISKOLC
71	Campus Universitario S.Venuta; Centro Oncologico T.Campanella	Pierfrancesco Tassone	ITALY	Calabria	CATANZARO
72	Policlinico Universitario Agostino Gemelli	CARLO BARONE	ITALY	Lazio	ROMA
73	AZIENDA OSPEDALIERO-UNIVERSITARIA DIPARTIMENTO INTERAZIENDALE DI ONCOLOGIA	Giovanni Cardellino	ITALY	Friuli-Venezia Giulia	UDINE
74	Ospedale Misericordia E Dolce; Oncologia Medica	Samantha Di Donato	ITALY	Toscana	PRATO
75	Irccs Ospedale S. Raffaele Di Milano	LUCA GIANNI	ITALY	Lombardia	MILANO
76	Azienda Ospedaliera Papa Giovanni XXIII;Oncologia Medica.	Stefania Mosconi	ITALY	Lombardia	BERGAMO
77	IRCCS Ospedale Casa Sollievo Della Sofferenza	EVARISTO MAIELLO	ITALY	Puglia	San Giovanni Rotondo
78	Azlenda Ospendaliero-Universitaria Pisana; C.O. Oncologia 2	ALFREDO FALCONE	ITALY	Toscana	Pisa
79	AO Santa Maria Nuova; U.O. Day Hospital di Oncologi	CORRADO BONI	ITALY	Emilia-Romagna	Reggio Emilia
80	Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica	Carmine Pinto	ITALY	Emilia-Romagna	BOLOGNA
81	AZ. OSP. UNI RIA SAN MARTINO; CLINICHE UNI RIE CONVENZIONATE U.O. ONCOLOGIA MEDICAL	SILVANA CHIARA	ITALY	Liguria	GENOVA
82	OSPEDALI RIUNITI DI ANCONA; ONCOLOGY	STEFANO CASCINU	ITALY	Marche	ANCONA
83	Irccs Istituto Europeo Di Oncologia (IEO); Oncologia Medica	Nicola Fazio	ITALY	Lombardia	MILANO
84	Seconda Universita' Degli Studi; Divsione Di Oncologia Medica	Ferdinando De Vita	ITALY	Campania	NAPOLI
85	SAITAMA CANCER CENTER; GASTROENTEROLOGY	Kensei Yamaguchi	JAPAN	Saitama	Saitama
86	Toyama University Hospital;Gastroenterology and Hematology	Ayumu Hosokawa	JAPAN	Toyama	Toyama
87	NATIONAL CANCER CENTER HOSPITAL EAST; GASTROENTEROLOGY	Kohei Shitara	JAPAN	CHIBA	CHIBA
88	NATIONAL CANCER CENTER HOSPITAL; GASTROINTESTINAL ONCOLOGY	Yasuhide Yamada	JAPAN	TOKYO	TOKYO
89	Kanagawa Cancer Center; Gastrointestinal Surgery	Takaki Yoshikawa	JAPAN	Kanagawa	Kanagawa
90	St.Marianna University School of Medicine hospital; Medical Oncology	NARIKAZU BOKU	JAPAN	Kanagawa	Kanagawa
91	Gifu University Hospital; Second Department of Surgery	Kazuhiro Yoshida	JAPAN	GIFU	GIFU
92	Nagoya university Hospital; Gastroenterological Surgery 2	Yasuhiro Kodera	JAPAN	Aichi	Aichi
93	Aichi Cancer Center Hospital; Clinical Oncology	KEI MURO	JAPAN	Aichi	Aichi
94	Osaka Medical Ctr for Cancer and Cardiovascular Diseases;Clinical oncology and Gastrointestinal onco	Naotoshi Sugimoto	JAPAN	Osaka	Osaka
95	Osaka General Medical Center; Surgery	Kazumasa Fujitani	JAPAN	Osaka	Osaka
96	Kobe city Medical center General Hospital; Medical Oncology	AKIHITO TSUJI	JAPAN	Hyogo	Hyogo
97	Hiroshima city Hospital; Surgery	Motoki Ninomiya	JAPAN	Hiroshima	Hiroshima
98	National Hospital Organization Shikoku Cancer Center; Gastroenterology	TOMOHIRO NISHINA	JAPAN	Ehime	Ehime
99	Kyushu University Hospital; Surgery and Science	Eiji Oki	JAPAN	Fukuoka	Fukuoka
100	YONSEI MEDICAL CENTER; DEPT. OF MEDICINE , DIVISION OF HEMATO-ONCOLOGY	SUN YOUNG RHA	KOREA, REPUBLIC OF	SEOUL	SEOUL
101	Asan Medical Center; Medical Oncology	YOON-KOO KANG	KOREA, REPUBLIC OF	SEOUL	SEOUL
102	SEOUL NATIONAL UNI HOSPITAL; DEPT. OF INTERNAL MEDICINE/HEMATOLOGY/ONCOLOGY	YUNG-JUE BANG	KOREA, REPUBLIC OF	SEOUL	SEOUL
103	Samsung Medical Center	Joon Oh Park	KOREA, REPUBLIC OF	SEOUL	SEOUL
104	Seoul St Mary's Hospital	Hoo Geun Chun	KOREA, REPUBLIC OF	SEOUL	SEOUL
105	Kyungpook National University Medical Center	JONG GWANG KIM	KOREA, REPUBLIC OF	DAEGU	DAEGU
106	University Clinic for Radiotherapy and Oncology	NATALIJA ANGELOVSKA	MACEDONIA	SKOPJE	SKOPJE
107	Clinical Hospital; Oncology Department	Petar Stefanovski	MACEDONIA	Bitola	Bitola
108	Hospital Wanita dan Kanak-Kanak Sabah	Flora Li Tze Chong	MALAYSIA	Sabah	Sabah
109	University Malaya Medical Centre; Clinical Oncology Unit,	Anita Bustam	MALAYSIA	Kuala Lumpur	Kuala Lumpur
110	Hospital Universiti Sains Malaysia	Biswa Mohan Biswal	MALAYSIA	Kelantan	Kelantan
111	Hospital Kuala Lumpur; Jabatan Radioterapi dan Onkologi	Natasha Mohd Hashim	MALAYSIA	Kuala Lumpur	Kuala Lumpur
112	HOSPITAL ANGELES METROPOLITANO; ROOM 220	Gloria Martinez	MEXICO	MEXICO CITY	MEXICO CITY
113	Oaxaca Site Management Organization	Carlos Alberto Hernandez	MEXICO	Oaxaca	Oaxaca
114	INST. NACIONAL DE CANCEROLOGIA; INVESTIGACION CLINICA	GERMAN CALDERILLO RUIZ	MEXICO	MEXICO CITY	MEXICO CITY
115	Academisch Medisch Centrum Universiteit Amsterdam	Hanneke van Laarhoven	NETHERLANDS	Amsterdam	Amsterdam
116	Medical Research Centre	ROBERTO IVAN LOPEZ	PANAMA	Panama	Panama
117	Oncocare	Carlos Desposorio	PERU	Miraflores	Miraflores
118	Instituto Oncologico Miraflore	FERNANDO SALAS	PERU	Lima	Lima
119	Centro Medico Monte Carmelo	Renzo Alvarez-Barreda	PERU	Arequipa	Arequipa
120	HOSPITAL SABOGAL; ONCOLOGY	Patricia Pimentel	PERU	CALLAO	CALLAO
121	Hosp Nacion Edgardo Rebagliati; Oncologia Medica	Luis Vera	PERU	Jesus Maria	Jesus Maria
122	Bialostockie Ctr Onkologii; Oddzial Chemioterapii Dziennej	MAREK WOJTUKIEWICZ	POLAND	BIALYSTOK	BIALYSTOK
123	Dolnoslaskie Centrum Onkologii	EMILIA FILIPCZYK-CISARZ	POLAND	WROCLAW	WROCLAW
124	Szpital Specjalistyczny Podkarpacki O？rodek Onkologiczny	Dariusz Sawka	POLAND	Brzozów	Brzozów
125	Centrum Onkologii - Instytut im. M. Sklodowskiej-Curie; Klinika Gastroenterologii Onkologicznej	Lucjan Wyrwicz	POLAND	WARSZAWA	WARSZAWA
126	SPZOZ Opolskie Centrum Onkologii im. Prof. Tadeusza Koszarawskiego	Kazimierz Drosik	POLAND	Opole	Opole
127	Wojewódzki Szpital Specjalistyczny Nr 3	Grzegorz Slomian	POLAND	Rybnik	Rybnik
128	Cardiomed Medical Center	Calin Cainap	ROMANIA	Cluj-Napoca	Cluj-Napoca
129	Institutul Oncologic Prof. Dr. Ion Chiricuta Cluj-Napoca; Oncologie Medicala - Radiologie I	CRISTINA CEBOTARU	ROMANIA	Cluj-Napoca	Cluj-Napoca
130	Euroclinic Center of Oncology SRL	Constantin Volovat	ROMANIA	Iasi	Iasi
131	SC Oncolab SRL	Michael Schenker	ROMANIA	Craiova	Craiova
132	INSTITUT ONCOLOGIC PROF. DR. ALEXANDRU TRESTIOREANU; DEPARTAMENT RADIOTERAPIE	RODICA ANGHEL	ROMANIA	BUCHAREST	BUCHAREST
133	State Budgetary Institution of Healthcare	EUGENI KULIKOV	RUSSIAN FEDERATION	Ryazan	Ryazan
134	SBI of Healthcare Samara Regional Clinical Oncology Dispensary	Mikhail Kopp	RUSSIAN FEDERATION	Samara	Samara
135	Clinical Oncology Dispensary; Chemotherapy	DMITRY VIUSHKOV	RUSSIAN FEDERATION	Omsk	Omsk
136	FSI Rostov research oncological institute of MoH and SD of RF; PAD	LYUBOV VLADIMIROVA	RUSSIAN FEDERATION	Rostov-on-Don	Rostov-on-Don
137	Hospital Duran i Reynals; Oncologia	M. Carmen Galan Guzman	SPAIN	Barcelona	Barcelona
138	Hospital Universitario Reina Sofia; Servicio de Oncologia	Enrique Aranda Aguilar	SPAIN	CORDOBA	CORDOBA
139	Hospital del Mar; Servicio de Oncologia	Rosa Gallego Sanchez	SPAIN	Barcelona	Barcelona
140	Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia	Jose Luis Manzano Mozo	SPAIN	Barcelona	Barcelona
141	Hospital de la Santa Creu i Sant Pau; Servicio de Oncologia	Marta Martin Richard	SPAIN	Barcelona	Barcelona
142	Hospital General Universitario de Elche; Servicio de Oncologia	Javier Gallego Plazas	SPAIN	ELCHE	ELCHE
143	Hospital Ramon y Cajal; Servicio de Oncologia	Federico Longo Mu？oz	SPAIN	Madrid	Madrid
144	Hospital Univ Vall d'Hebron; Servicio de Oncologia	Josep Maria Tabernero Cartula	SPAIN	Barcelona	Barcelona
145	Luzerner Kantonsspital; Medizinische Onkologie	RALPH WINTERHALDER	SWITZERLAND	Luzern	Luzern
146	CHUV; Departement d'Oncologie	Anna Dorothea Wagner	SWITZERLAND	Lausanne	Lausanne
147	Taipei Veterans General Hospital	YEE CHAO	中国	Taipei	Taipei
148	NATIONAL TAIWAN UNI HOSPITAL; DEPT OF ONCOLOGY	KUN-HUEI YEH	中国	Taipei	Taipei
149	Chang Gung Medical Foundation - Linkou; Division of Hematology- Oncology	JEN-SHI CHEN	中国	Taoyuan	Taoyuan
150	National Cheng Kung Unversity Hospital; Oncology	Chia-Jui Yen	中国	Tainan	Tainan
151	TAICHUNG VETERANS GENERAL HOSPITAL; DEPT OF SURGERY	CHENG-CHUNG WU	中国	Taichung	Taichung
152	FACULTY OF MED. SIRIRAJ HOSP.; MED.-DIV. OF MED. ONCOLOGY	VICHIEN SRIMUNINNIMIT	THAILAND	BANGKOK	BANGKOK
153	PRINCE OF SONGKLA UNI ; UNIT OF MEDICAL ONCOLOGY	Arunee Dechaphunkul	THAILAND	SONGKHLA	SONGKHLA
154	King Chulalongkorn Memorial Hospital; Faculty of Medicine Chulalongkorn University	VIROTE SRIURANPONG	THAILAND	BANGKOK	BANGKOK
155	RAMATHIBODI HOSPITAL; DEPT OF MED.-DIV. OF MED. ONC	Ekaphop Sirachainan	THAILAND	BANGKOK	BANGKOK
156	Rajavithi Hospital; Division of Medical Oncology	Sudsawat Laohavinij	THAILAND	Bangkok	Bangkok
157	Khonkaen Hospital	Dr. Parichat Phongthai	THAILAND	Khonkaen	Khonkaen
158	Akdeniz University Medical Faculty; Medical Oncology Department	HAKAN BOZCUK	TURKEY	Antalya	Antalya
159	Trakya University Medical Faculty Research And Practice Hospital Medical Oncology Department	Irfan Cicin	TURKEY	EDIRNE	EDIRNE
160	Ataturk University Medical Faculty Yakutiye Research Hospital Medical Oncology Department	Salim Basol Tekin	TURKEY	ERZURUM	ERZURUM
161	TC Necmettin Erbakan University Meram Medical Faculty Hospital	Cem Boruban	TURKEY	Konya	Konya
162	ANKARA UNI SCHOOL OF MEDICINE; MEDICAL ONCOLOGY	HAKAN AKBULUT	TURKEY	ANKARA	ANKARA
163	ISTANBUL UNI CERRAHPASA MEDICAL FACULTY HOSPITAL; MEDICAL ONCOLOGY	MUSTAFA OZGUROGLU	TURKEY	ISTANBUL	ISTANBUL
164	Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department	Hakan Harputluoglu	TURKEY	MALATYA	MALATYA
165	Indiana University Health; Goshen Center for Cancer Care	Alexander Starodub	UNITED STATES	IN	Goshen
166	Northwest Medical Specialties, PLLC	Frank Senecal	UNITED STATES	WA	Tacoma
167	Rocky Mountain Cancer Centers, LLP	ALLEN L. COHN	UNITED STATES	CO	Denver
168	NEW YORK ONCOLOGY HEMATOLOGY, P.C.	Linda DeMarco	UNITED STATES	NY	Albany
169	Texas Oncology, P.A. - Tyler; Tyler Cancer Center	DONALD RICHARDS	UNITED STATES	TX	Tyler
170	Virginia Cancer Specialists, PC	Alexander I. Spira	UNITED STATES	VA	Fairfax
171	University Of Chicago Medical Center; Section Of Hematology/Oncology	Daniel Catenacci	UNITED STATES	IL	CHICAGO
172	Queens Medical Associates	Barry H. Kaplan	UNITED STATES	NY	FRESH MEADOWS
173	MINNESOTA ONCOLOGY HEMATOLOGY, PA	PATRICK J. FLYNN	UNITED STATES	MN	Minneapolis
174	Texas Oncology - Lake Vista	Derrick Nguyen	UNITED STATES	TX	LEWISVILLE
175	Texas Oncology - Paris	SUCHARU PRAKASH	UNITED STATES	TX	Paris
176	COMPREHENSIVE CANCER CENTERS OF NEVADA - EASTERN AVENUE	Fadi Braiteh	UNITED STATES	NV	Las Vegas
177	Medical University of South Carolina; Hollings Cancer Center	Steve Chin	UNITED STATES	SC	Charleston
178	Tennessee Oncology	Johanna Bendell	UNITED STATES	TN	Nashville
179	Florida Cancer Specialists.	Peter Acs	UNITED STATES	FL	St.Petersburg
180	Florida Cancer Specialists - SCRI; Pharmacy	James Reeves	UNITED STATES	FL	Fort Myers
181	Oncology Hematology Care	Irfan Firdaus	UNITED STATES	OH	Cincinnati
182	Cancer Institute of Florida PA	Ahmed Zakari	UNITED STATES	FL	Orlando
183	Wojewódzki Szpital Specjalistyczny Nr 3	Slomian Grzegorz	POLAND	Katowice	Rybnik
184	NZOZ Centrum Medyczne HCP Sp. z o.o.	WOJCIK ELZBIETA	POLAND	Województwo mazowieckie	Warsaw
185	Szpital Uniwersytecki w Krakowie, Oddzia？ Kliniczny Kliniki Onkologii	Wysocki Piotr	POLAND	Krakow	Krakow
186	CENTRUM ONKOLOGII;IM. FRANCISZKA LUKASZCZYKA;ONKOLOGII	CHMIELOWSKA EWA	POLAND	Kujawsko-Pomorskie	BYDGOSZCZ
187	Weill Medical College of Cornell University; Division of Hematology & Medical Oncology	Shah Manish	UNITED STATES	NY	New York
188	Complex Oncological Center - Plovdiv, EOOD	TOMOVA ANTOANETA	BULGARIA	Plovdiv	Plovdiv
189	Kazakh Scientific Research Institution Of Oncology and Radiology; Chemotherapy department	Nurgaziyev Kuanysh	KAZAKHSTAN	Almaty	Almaty
190	CLINICAL ONCOLOGY DISPENSARY OF MINISTRY OF HEALTH OF TATARSTAN	Kuzmin Alexey	RUSSIAN FEDERATION	KAZAN	KAZAN
191	Philipps-Universit？t Marburg; Klinik für Innere Med.; Schwerpunkt H？matologie/Onkologie/Immunologie	Riera-Knorrenschild Jorge Ramon Urrico	GERMANY	Marburg	Marburg
192	Hospital Universitario 12 de Octubre; Servicio de Oncologia	Gomez Martin Carlos	SPAIN	MADRID	MADRID
193	TORONTO EAST GENERAL HOSPITAL; HAEMATOLOGY/ONCOLOGY	Shao Richard	CANADA	Toronto	Ontario

1	组织学证实（患者入组所在中心）为转移性胃腺癌或胃食管交界处腺癌
2	HER2-阳性肿瘤，定义为IHC 3+或IHC 2+/ISH+，由申办方指定的中心实验室对原发瘤或转移瘤进行检测后决定(注：ISH阳性定义为HER2基因复制的数量与17号染色体着丝粒(CEP17)信号数量的比值≥2.0。IHC评分采用了美国食品药品监督管理局(FDA) 根据ToGA研究所批准的截止点。患者必须提供福尔马林固定石蜡包埋(FFPE)肿瘤组织供中心实验室确认HER2表达状况。)
3	患者存在可测量或可评价的不可测量病灶；由研究者根据实体瘤的疗效评价标准(RECIST) v1.1进行评价。
4	东部肿瘤协作组行为状态评分(ECOG PS)为0或1
5	预期寿命≥3个月
6	年龄≥18岁
7	研究者评估认为患者能遵照方案要求
8	签署知情同意文件

1	曾因晚期（转移性）疾病进行过全身细胞毒性药物化疗
2	曾暴露于下列累积剂量的蒽环类药物：a) 表柔比星＞720 mg/m2；b) 多柔比星或多柔比星脂质体>360 mg/m2；c) 米托蒽醌>120 mg/m2和伊达比星>90 mg/m2；d) 其他（例如，大于相当于360 mg/m2多柔比星的多柔比星脂质体或其他的蒽环类）；e) 如果使用一种以上的蒽环类药物，则其累积剂量不能超过相当于360 mg/m2的多柔比星。
3	有证据表明因胃腺癌或胃食管交界处腺癌完成新辅助化疗或辅助性细胞毒药物化疗（或两者皆有）或放疗之后的6个月内出现疾病进展者
4	以往在任意时间，曾接受过任意疗程的HER2-直接治疗
5	以往在任意时间，曾接受过任意疗程的HER2-直接治疗
6	在使用第一剂研究药物治疗之前30天内进行放疗（2周内，如果是对外周骨转移进行姑息治疗并从所有毒性中恢复）
7	有脑转移的病史或证据
8	有临床意义的胃肠道出血（根据美国国立癌症研究所[NCI]不良事件通用术语标准[CTCAE] v4.03，等级≥2）
9	以前接受的治疗存在残留毒性（例如，等级≥2的血液系统、心血管系统或神经毒性）。允许存在脱发。
10	在入组前5年内发生其他恶性肿瘤(GC之外)，之前曾以根治为目的进行治疗的子宫颈原位癌或皮肤鳞状或基底细胞癌除外
11	中性粒细胞绝对计数(ANC)<1.5 ×109/L
12	血小板计数<75 × 109/L
13	血红蛋白<9.0 g/dL
14	肌酐清除率(CL)<60 mL/min/1.73 m2
15	血清胆红素(总)>1.5倍实验室正常值范围上限(ULN)；如发生已知的Gilbert病，总胆红素最高到2倍ULN是允许的。
16	AST、ALT和碱性磷酸酶(ALP)参数：a) 无肝转移且无骨转移的患者 i. AST或ALT>1.5 × ULN，且ALP>2.5 × ULN；ii. AST或ALT>2.5 × ULN。 b) 有肝转移且无骨转移的患者 i. AST或ALT>5 × ULN，且ALP>2.5 × ULN。c) 有肝转移且有骨转移的患者 i. AST或ALT>5 × ULN，且ALP>10 × ULN。d) 有骨转移且无肝转移的患者 i. AST或ALT>1.5 × ULN，且ALP>10 × ULN
17	血清白蛋白<25 g/L
18	育龄期女性患者血清妊娠试验呈阳性
19	根据纽约心脏协会(NYHA)标准有充血性心力衰竭的病史记录
20	患有需进行治疗的心绞痛
21	在使用第一剂研究药物治疗之前的6个月内曾发生心肌梗死
22	临床显著的心脏瓣膜病或无法控制的高风险的心律失常（即房性心动过速，静息心率>100/min），显著的室性心律失常（室性心动过速）或高度房室传导阻滞（2级II型AV-阻滞 [Mobitz 2]或3级AV-阻滞）
23	有动脉性高血压控制不佳的病史或证据（收缩压>180 mmHg或舒张压>100 mmHg）
24	经超声心动图(ECHO)、心脏放射性核素扫描(MUGA)或心脏磁共振成像(MRI)扫描评价，基线左心室射血分数(LVEF)值<55%
25	因晚期恶性肿瘤并发症或其他疾病而引起静息时呼吸困难或需要吸氧进行支持治疗
26	任何重大的未控制的全身间发性疾病（例如，活动性感染、控制不佳的糖尿病）
27	在给予第一剂研究治疗前30天内前曾进行过大手术，除非完全恢复
28	已知患有HIV、乙肝病毒、或丙肝病毒感染，需进行积极治疗
29	正在接受长期或高剂量皮质类固醇类治疗。允许适用吸入性类固醇以及按临床指征的短期口服类固醇类。
30	已知患有二氢嘧啶脱氢酶（DPD）缺乏症
31	已知对研究治疗中的任何成分过敏
32	正在使用抗病毒药物索立夫定或其化学相关的类似物，如溴夫定
33	哺乳期女性患者
34	在研究治疗期间及给予最后一剂帕妥珠单抗或曲妥珠单抗后至少6个月内，任何不愿或不能采用适当避孕措施的患者，除非患者有曾行绝育手术的记录或是已绝经的女性

相关临床试验招募信息

常见问题